Alibaba Health

ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 00241)

GRANT OF RESTRICTED SHARE UNITS

GRANT OF RESTRICTED SHARE UNITS

On September 15, 2026, the Company granted a total of 7,672,500 RSUs to 16 Grantees in accordance with the terms of the 2024 Share Award Scheme, subject to acceptance.

This announcement is made pursuant to Rules 17.06A, 17.06B and 17.06C of the Listing Rules.

RESTRICTED SHARE UNITS

On September 15, 2026, the Company granted a total of 7,672,500 RSUs to 16 Grantees in accordance with the terms of the 2024 Share Award Scheme, subject to acceptance. The details of the grant of the RSUs are as follows:

Date of Grant	:	September 15, 2026
Grantees	:	A total of 7,672,500 RSUs are granted to the Grantees, who are employees of the Group

Number of RSUs granted	:	7,672,500 Each of the RSUs granted to the Grantees represents a right to receive a Share on the date the RSU vests
Purchase price for the grant of RSUs	:	Nil
Closing price of the Shares on the Date of Grant	:	HK$2.925 per Share
Vesting period of the RSUs	:	Subject to any alteration by the Company as stated in separate grant letters between the Grantees and the Company, the RSUs granted to the Grantees shall vest by batches over four years from the Date of Grant, save for the RSUs granted to one Grantee (the "**Designated Employee**"). Each of the Grantees is not a Director or a member of senior management of the Company. In the event that any circumstances as specified in the respective grant letter arise, any RSUs granted to the Grantees but unvested will automatically lapse and not be exercisable in respect of the underlying Shares with effect upon the occurrence of the relevant circumstances The RSUs granted have mixed vesting schedules, with certain RSUs that may be vested within 12 months from the Date of Grant. According to the 2024 Share Award Scheme, the Board or the Remuneration Committee (as the case may be) is entitled to impose any terms and conditions as it deems appropriate in its absolute discretion with respect to the vesting of the RSUs provided that the vesting period for the RSUs shall not be less than 12 months unless under specific circumstances set out in the 2024 Share Award Scheme. It is permitted under the 2024 Share Award Scheme to have a vesting period shorter than 12 months, given that these RSUs (i) shall vest evenly over a period of 12 months or more; and/or (ii) were granted subject to the fulfilment of performance targets (as opposed to time-based conditions), falling under the specific circumstances allowed under the 2024 Share Award Scheme

Performance targets	:	Apart from the RSUs granted to the one Designated Employee, none of the remaining RSUs granted are subject to performance targets The vesting of the aforementioned RSUs granted to the Designated Employee is based on the fulfilment of performance targets as determined by the Board in its absolute discretion. The performance targets are based on certain operational indicators of the Group, as assessed by the Board from time to time
Clawback mechanism	:	In the event that any circumstances as specified in the respective grant letter arise, which include among others, the termination of the Grantee's employment or service by the Company or any of its subsidiaries by reason of the employer terminating the contract of employment without notice or payment in lieu of notice, the Grantee has committed an act of theft, embezzlement, fraud, dishonesty, ethical breach or other similar acts or the commission of a criminal offence or any conduct that is materially adverse to the name, reputation or interests of the Group, the RSUs granted but unvested will automatically lapse in respect of the underlying Shares with effect upon the occurrence of the relevant circumstances

In relation to the 7,672,500 RSUs granted to the Grantees, new Shares that rank *pari passu* in all respects among themselves and with all the Shares in issue from time to time shall be issued and/or existing Shares in issue to be purchased from the market out of cash contributed by the Company and held on trust for the Grantees shall be transferred to the Grantees (as the case may be) upon vesting and settlement of such RSUs.

REASONS FOR AND BENEFITS OF THE GRANTS

The purpose of the aforesaid grant of the RSUs is to (i) attract skilled and experienced personnel for the further development and expansion of the Group by providing them with the opportunity to acquire equity interests in the Company, (ii) recognize the contribution to the success and development of the Group made by the existing employees of the Group, and/or (iii) generally incentivize and motivate our employees to remain with, and to strive for the future development and expansion of, the Group.

LISTING RULES IMPLICATIONS

Save as disclosed above and to the best of the knowledge of the Directors having made all reasonable enquiries, as at the Date of Grant, (i) none of the other Grantees is a Director, chief executive or substantial shareholder of the Company or an associate (as defined under the Listing Rules) of any of them; (ii) none of the Grantees is a participant with Options and the RSUs granted and to be granted exceeding the 1% individual limit under Rule 17.03D(1) of the Listing Rules; (iii) none of the Grantees is a related entity participant or a service provider (as defined under the Listing Rules); and (iv) no financial assistance has been provided by the Group to the Grantees to facilitate the purchase of Shares under the 2024 Share Award Scheme.

NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT

The Stock Exchange has previously granted its approval of the listing of, and permission to deal in, new Shares which may be issued pursuant to the vesting or exercise of any Options and RSUs which may be granted pursuant to the 2024 Share Award Scheme. Upon the aforesaid grant of the Options and the RSUs, 1,480,191,026 Shares underlying the Options and the RSUs are available for future grant under the scheme mandate limit of the 2024 Share Award Scheme, and 160,917,362 Shares underlying the Options and the RSUs are available for future grant under the service provider sublimit of the 2024 Share Award Scheme.

DEFINITIONS

"2024 Share Award Scheme"	the share award scheme adopted by the Company at the annual general meeting on August 30, 2024, the principal terms of which were set out in Appendix II to the Company's circular dated July 30, 2024
"Board"	the board of directors of the Company
"Company"	Alibaba Health Information Technology Limited, a company incorporated in Bermuda, the shares of which are listed on the Main Board of the Stock Exchange (stock code: 00241)
"Date of Grant"	September 15, 2026
"Director(s)"	director(s) of the Company
"Grantees"	employees of the Group who are granted RSUs in accordance with the 2024 Share Award Scheme on the Date of Grant
"Group"	the Company and its subsidiaries
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong

"Hong Kong"	Hong Kong Special Administrative Region of the People's Republic of China
"Listing Rules"	Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
"Option(s)"	option(s) to subscribe for or acquire Shares which is/are granted under the 2024 Share Award Scheme
"Remuneration Committee"	the remuneration committee of the Company
"RSU(s)"	restricted share unit(s), being a contingent right to receive Share(s) which is/are awarded under the 2024 Share Award Scheme
"Shares"	ordinary shares of HK$0.01 each in the issued capital of the Company
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary"	has the same meaning ascribed to it under the Listing Rules

For and on behalf of the Board
Alibaba Health Information Technology Limited
Yu Yong
Chairman and Chief Executive Officer

Hong Kong, September 15, 2026

As at the date of this announcement, the Board comprises Mr. Yu Yong, Mr. Shen Difan and Ms. Sheng Mengyue as the executive Directors; Ms. Huang Jiaojiao as the non-executive Director; and Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong as the independent non-executive Directors.